Company intelligence / Profile preview
Yoda Pharmaceuticals Inc.
Taipei, Taipei City, Taiwanyodapharma.com ↗
- Ownership
- Private
- Employees
- ~10
- Development stage
- Preclinical
01
Overview
YA‑101, a dual NMDA/NLRP3 modulator, has shown efficacy in animal models with good safety profiles. It aims to address negative/cognitive symptoms of schizophrenia, early Alzheimer’s disease, and motor deficits in MSA. Most assets remain preclinical; no published human efficacy data yet.
- Therapeutic areas
- PsychiatryNeurology
- Modalities
- Small moleculesChemical drugsNMDA modulatorsNLRP3 inflammasome modulators
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
No major pharma partnerships publicly disclosed as of May 2025. Some academic collaborations noted below.
Beyond the preview
Go deeper on Yoda Pharmaceuticals Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Yoda Pharmaceuticals Inc..